---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-26-000003"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:13:23.868568+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Entrada reports ~$296M cash, completes DMD cohort 1, expands pipeline into ocular disease with ENTR-801

## Summary
- Preliminary cash, cash equivalents and marketable securities of ~$296M as of Dec 31, 2025; cash runway into Q3 2027.
- Completed dosing of Cohort 1 in global Phase 1/2 MAD study of ENTR-601-44 (exon 44 skipping) for DMD.
- On track to report ELEVATE-44-201 data from first cohort in Q2 2026; ELEVATE-45-201 data in mid-2026.
- Received UK MHRA authorization for Phase 1/2 ENTR-601-50; expect global initiation by end 2026 and regulatory apps for ENTR-601-51 in 2026.
- Expanded into ocular diseases: selected ENTR-801 (Usher syndrome type 2A) as first candidate; expects second candidate in 2026.

## SEC filing metadata
- accession: 0001689375-26-000003
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937526000003/0001689375-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937526000003/trda-20260108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-26-000003
- JSON: https://secwatch.observer/filing/0001689375-26-000003.json
- Plain text: https://secwatch.observer/filing/0001689375-26-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.